The European Medicines Agency opened consultation on revision 2 of VICH GL49 on 13 November 2026, seeking comments by 30 April 2027 on analytical-method validation for veterinary drug residue-depletion studies. For research laboratories and regulatory study teams, the draft concerns the evidence supporting residue measurements and the records behind those results.
EMA releases the draft for comment
The 22-page consultation document records agreement by the VICH Steering Committee in October 2026, adoption by EMA’s Committee for Veterinary Medicinal Products for consultation on 5 November, and transmission to interested parties on 13 November. These are stages in the development of guidance: the release invites scrutiny of a draft rather than announcing a final standard taking effect.
EMA’s November committee meeting highlights also describe a six-month consultation ending in April 2027. The document belongs to the international VICH programme for harmonising technical requirements for veterinary medicinal products. Its stated objective is to describe validation criteria considered suitable across the participating regulatory regions.
Two consultation calendars need separate attention
The EMA cover gives an exact closing date of 30 April 2027. Separately, the VICH secretariat’s activities page lists GL49(R2) as an October 2026 Step 4 release, with a global consultation period ending on 25 April 2027. The dates therefore refer to different published consultation calendars; the VICH listing should not be substituted for EMA’s deadline.
For institutions coordinating comments across countries, the practical implication is to identify the receiving consultation route before setting an internal deadline. A consolidated response intended for the global VICH process needs to account for its earlier listed date, while a response to EMA follows the agency’s published timetable.
The scope is study evidence, with a separate role for monitoring methods
GL49 addresses analytical procedures used to measure veterinary drug residues in marker residue-depletion studies. The draft describes edible animal products including tissues, milk, eggs and honey. Those measurements form part of the evidence generated during veterinary drug development and submitted to regulators.
The distinction from regulatory monitoring is explicit. Section 2.2 excludes defining the validation criteria for regulatory monitoring assays. The background explains that an internally validated study method may later provide a basis for a regulatory control method, but that later phase is outside the document’s detailed treatment. A laboratory reviewing the consultation therefore needs to establish which use of its assay is under discussion.
This is a specific part of the wider analytical process: demonstrating that a measurement procedure produces suitable evidence for its intended study purpose. A monitoring laboratory and a development-study laboratory may work on related residues, yet this draft does not treat their validation purposes as interchangeable.
What the draft says about validation evidence
The consultation text organises method performance around nine characteristics: linearity, accuracy, precision, detection and quantitation limits, selectivity, stability in the original matrix, stability after sample processing, and robustness. These are provisions described in the draft, rather than a claim that each characteristic has been newly introduced by revision 2.
Its treatment of accuracy and precision illustrates the evidence reviewers can examine. Accuracy concerns agreement between the true analyte concentration and the average measured result. Precision addresses consistency between measurements, including variation within an analytical run and between runs. The draft explains that between-laboratory reproducibility generally need not be established for a residue-depletion study when method development and sample analysis occur in the same laboratory.
The sections on detection and quantitation limits allow scientifically valid approaches supported by a scientific justification. The distinction matters when reviewing a validation report: evidence that an analyte can be detected addresses a different question from evidence that it can be measured with acceptable accuracy and precision. The annexes provide examples for estimating those limits.
Stability receives separate treatment for the original sample matrix and for a processed sample extract. Robustness concerns the effect of variations in method conditions that could influence performance. Together, these sections give study teams concrete topics for assessing whether the draft adequately addresses their analytical evidence.
Validation records matter to research offices
The draft draws a further distinction relevant to university laboratories and research organisations. It states that residue studies must use validated methodology under Good Laboratory Practice, while the method-validation experiments themselves fall outside the scope of GLP regulations. It nevertheless calls for raw validation data to be archived appropriately and available to regulatory authorities on request.
For research offices supporting this work, that makes the consultation relevant to records as well as instruments. An evidence-focused review can connect the reported performance of a method with the underlying validation results and their retention. The archiving provision also connects the scientific assessment to data integrity: keeping a defensible record of how the reported result was obtained.
Independent coverage and the next steps
In its 16 November regulatory brief, Gulfstream Intelligence founder Scott Morvay reported the availability of revision 2 for consultation and identified EMA’s veterinary consultations as opportunities to comment on analytical-method validation and pharmacovigilance terminology. That framing places the immediate action at the consultation stage.
Laboratories and institutional regulatory teams can use the comment period to examine the draft’s scope, performance criteria and documentation expectations against the work they submit for regulatory assessment. EMA’s next dated milestone is the close of comments on 30 April 2027; the VICH secretariat separately lists 25 April. The draft describes subsequent recommendation of a final text to regulatory bodies through the VICH process, without giving a final implementation date.
Sources
- European Medicines Agency: VICH GL49, validation of analytical methods used in residue depletion studies, revision 2, 13 November 2026; checked 2026-11-17.
- European Medicines Agency: Meeting highlights from the CVMP, 3–5 November 2026, November 2026; checked 2026-11-17.
- VICH secretariat: Activities, draft guidelines for public consultation, GL49(R2) listing dated October 2026; checked 2026-11-17.
- Gulfstream Intelligence: MHRA sets women’s health agenda, EMA opens veterinary consultations, 16 November 2026; checked 2026-11-17.







